Lefamulin safety and effectiveness in pneumonia
Part of Infections, Lungs & breathing clinical trials.
This study watches how well the antibiotic lefamulin works in real-life patients with community-acquired pneumonia. It helps doctors understand the drug's safety and effectiveness outside of a controlled research setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have community-acquired pneumonia (a lung infection you got outside of a hospital).
- Your doctor has decided that you should take or are already taking the antibiotic lefamulin.
- You are not allergic to lefamulin or similar antibiotics.
- Your lung infection is not caused by something like a blood clot, heart failure, or a tumor.
- You do not have an infection in the space between your lung and chest wall (empyema).
- You are not in any other experimental treatment study right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving antibiotics directly into the lungs can help treat severe pneumonia. If you have been hospitalized with pneumonia and have a high fever or high inflammation levels, you may be eligible.
This trial compares different antibiotic strategies for children with pneumonia who are being treated as outpatients. The goal is to find the best approach to treat the infection and help your child recover.
This study looks at adults with pneumonia caught outside the hospital. It aims to understand what symptoms they have and how well they recover, which could help doctors treat this condition better.
This trial tests a new antibiotic called HRS-8427 for adults with bacterial pneumonia that started in the hospital or while on a ventilator. It may be an option if you need IV antibiotics and haven't already received long-term treatment for this infection.
This trial tests a new antibiotic (omadacycline) compared to a standard one (moxifloxacin) for adults with community-acquired pneumonia. The goal is to see if the new drug is as safe and effective.
This study tests whether the antibiotic clarithromycin can prevent pneumonia from getting worse and turning into sepsis. It is for adults with community-acquired pneumonia who have certain signs of infection in their blood.
Hear when a new Community-Acquired Pneumonia (CAP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.